Ann: MEETING: PEB: Results of AGM

• Release Date: 06/09/13 17:41
• Summary: MEETING: PEB: Results of AGM
• Price Sensitive: No
• Download Document  3.42KB

					

PEB
06/09/2013 15:41
MEETING

REL: 1541 HRS Pacific Edge Limited

MEETING: PEB: Results of AGM

Results of the Pacific Edge Annual General Meeting
Held 22nd August 2013

6th September 2013

Pacific Edge Limited advises that the following Ordinary Resolutions were
passed at its Annual General Meeting:

(a) That Anatole Masfen be re-elected as a Director of the Company;
(b) That Colin Dawson be re-elected as a Director of the Company;
(c) That Bryan Williams be elected as a Director of the Company;
(d) That PricewaterhouseCoopers be re-appointed as the Company's auditors and
the Directors of the Company be authorised to fix the auditors remuneration
for the ensuing year;
(e) That pursuant to clause 25 of the Company's Constitution and NZSX Listing
Rule 3.5.1 the maximum aggregate amount per annum payable by the Company to
the Directors, in their capacity as Directors, be increased to $172,000.

Biographical Information of Director:

Anatole Masfen
Anatole Masfen is the co-founder of Artemis Capital a private equity
investment firm based in Auckland. Anatole brings to the Board, significant
experience as an investment manager.

Anatole graduated from Auckland University with a MCom (Hons) in Finance and
Economics. He then spent seven years at Air New Zealand and Ansett Australia
in various roles in Pricing and Revenue Management where he was responsible
for systems and process implementation, which continue to drive profitability
of the airline.

Colin Dawson
Colin has a broad background within the Life Sciences sector. Following 10
years in veterinary clinical practice he held a number of senior executive
positions in the public and private healthcare sectors. Prior to taking up
his current role, Colin was Director Group Strategy with healthcare REIT The
Calan Group and a founding partner in health consulting and
investment-banking services firm Medicus Capital.

In addition to his current role as CEO of Otago Innovation Limited, the
commercialisation arm of the University of Otago, Colin serves on the
Advisory Boards of NZ BIO and the Otago Brain Health Research Centre, and is
a director of a number of NZ technology and biotechnology companies including
Immune Solutions Ltd. BLIS Technologies and Menixis Ltd. Colin is a Trustee
of the Upstart Business Incubator, an Accredited Fellow of the NZ Institute
of Directors and an SEP alumnus of the Stanford University Graduate School of
Business.

Bryan Williams
Bryan Williams is an internationally recognized cancer researcher and
research administrator with significant business experience. He was chairman
of the Board of Directors of MEI Pharma, a NASDAQ listed company for seven
years, is presently chairman of the Board of Biograd Australia, and a
Director of Cancer Trials Australia.  He has served as a Director of Pacific
Edge Pty Ltd for the past 4 years. Bryan has been Director of the Monash
Institute of Medical Research since 2006 and previously held leadership
positions in Cleveland and Toronto.

Director Independence

Independent Directors per listing rule 3.3.1.A, 3.3.1B:
The following are Independent Directors:

- Chris Swann
- David Band
- Bryan Williams

The following Directors are not Independent due to Disqualifying
Relationships under the Listing Rules: 3.3.1

- Colin Dawson
-      Anatole Masfen

For further information please contact:
Investor Relations Manager
Email: [email protected]
Ph:  +64 3 479 5806
End CA:00240832 For:PEB    Type:MEETING    Time:2013-09-06 15:41:47